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Abstract
Background: The ideal prosthesis for aortic valve replacement in children and young adults has
not been found yet. In recent years there has been a renewed interest in the replacement of aortic
valve with the pulmonary autograft owing to its advantages of lack of anticoagulation, potential for
growth and excellent haemodynamic performance. The purpose of this study was to review our
institutional experience at Alder Hey hospital with the Ross procedure in children and young
adults.
Methods: From November 1996 to September 2003, 38 patients (mean age, 13.1 ± 5.7 years)
underwent the Ross procedure for various aortic valve diseases using the root replacement
technique. Clinical and echocardiographic follow-up was performed early (within 30 days), 3 to 6
months, and yearly after surgery. Medical records of all patients were reviewed retrospectively.
Results: There was 1 perioperative death. The patients were followed-up for a median interval of
36 months and up to 7 years. One patient died 3 years after surgery secondary to ventricular
arrhythmia with overall mortality of 5.3%. Actuarial survival at 7 years was 94 ± 2.5% and there was
100% freedom from reoperation for autograft valve dysfunction or any other cause. Balloon
dilatation was required in 2 patients for pulmonary homograft stenosis. The haemodynamics at the
latest follow-up were also similar to those at the time of discharge after surgery. There was no
progression in the degree of aortic regurgitation for 11 patients with trivial and 3 with mild
regurgitation.
Conclusion: Our experience demonstrates that Ross operation is an attractive option for aortic
valve replacement in children and young adults. Not only can the operation be accomplished with
a low operative risk but the valve function stays normal over a long period of time with minimal
alteration in lifestyle and no need for repeated operations to replace the valve as a result of somatic
growth of the children.
Background
The original investigative work that led to the Ross opera-
tion was first reported by Pillsbury and Shumway in 1966
[1]. Ross first reported his clinical experience with replace-
ment of the aortic and mitral valves with a pulmonary
autograft in 1967 [2]. Initially there was a reluctance to
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accept the technique of Ross owing to the complexity of
the procedure and the unknown fate of the pulmonary
autograft. In those days classic valvular prostheses were
regarded as the usual option for aortic valve replacement.
Nowadays, it is obvious that aortic valve replacement with
the classic valvular prostheses is not without the well
known disadvantages of degeneration of bioprostheses
[3], thrombo-embolic phenomena and anticoagulation-
related bleeding due to mechanical prostheses [4], and
need for repeated operations in younger patients due to
continued somatic growth. The ideal valve replacement,
particularly in a child, ought to be accomplishable with a
low operative risk. It should restore normal valve func-
tion, and ventricular function should be returned to as
close to normal as possible. In addition, it should require
minimal alteration in lifestyle, it should have perma-
nency, and the replacement of the valve should not be
required with the somatic growth of the child. Impressed
by the results of Ross [2] and other authors [5-8], we
started this procedure in November 1996 at our institu-
tion. The purpose of this study was to review our institu-
tional experience with the Ross procedure in children and
young adults.
Methods
Study design
The study is a retrospective review focusing on 7-years
experience of Ross procedure in children and young
adults. All patients who underwent Ross procedure
between November 1996 and September 2003 were
included in this study. Medical records and charts were
reviewed for demographic data, original anatomic diag-
noses, prior interventions and details of operative proce-
dure including technical data. Perioperative course and
follow-up data was reviewed for conduction abnormali-
ties and arrhythmias, duration of ventilation, neurologi-
cal sequelae, other postoperative issues and postoperative
interventions. All patients underwent detailed clinical and
echocardiographic examination early (within 30 days), 3
to 6 months and yearly after surgery.
Patients
Thirty eight patients (28 males and 10 females) under-
went replacement of the aortic valve by a pulmonary
autograft (Ross procedure) between November 1996 and
September 2003 as shown in Figure 1. The mean age of
the group was 13.1 ± 5.7 years at the time of surgery
(median 12.8, range, 1.4–29.7 years). The frequency dis-
tribution of age at Ross procedure shown in Figure 2
reveals that most patients underwent surgery below the
age of 20 years. Demographic details, dominant valve
pathology and hemodynamic lesions are shown in Table
1. Twenty seven patients had undergone previous aortic
valve interventions. One patient had balloon dilatation
on 3 separate occasions while another had balloon dilata-
tion twice prior to Ross procedure. Two patients had aortic
valve repair prior to replacement with pulmonary
autograft. One of these patients needed surgery to reattach
an aortic cusp which was detached following attempted
balloon dilatation. Two of the children had previous sur-
gery for repair of coarctation of aorta and ventricular sep-
tal defect, respectively. One patient had a mechanical
prosthetic valve which needed replacement due to
somatic growth of the patient. The mean follow-up was
33.2 ± 19.1 months (Median 36 months; range, 6–84
months) and was 100% complete.
Surgical technique
All operations were performed by the same surgeon
(M.P.). Standard cardiopulmonary bypass with moderate
hypothermia (28°C) was used. Myocardial protection
was achieved by antegrade cold blood cardioplegia at 4°C
infused through the aortic root or directly into the coro-
Yearly distribution of Ross procedure Figure 1
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nary ostia. Cardioplegia infusions were repeated every 20
minutes. The left ventricle was vented through the left
atrium in all cases.
The aortic valve was exposed through a transverse aortot-
omy. This allowed excellent exposure of the valve. All
patients underwent aortic root replacement with coronary
reimplantation using pulmonary autograft. In all cases a
continuous running suture technique was used. In all,
except two patients there were no, or only minor discrep-
ancies between the "annulus" and the autograft which
were addressed during suturing of the autograft and by
using a wider muscle cuff on the pulmonary artery. The
aortic "annulus" in effect takes the form of the cylindrical
root in which the valvar leaflets are supported in a crown-
like fashion [9]. Plication of the annulus had to be done
in the two patients with a significantly dilated annulus
which was more than 3 millimetres larger than the
autograft. A horizontal mattress stitch of 4/0 monofila-
ment suture (Ethicon, Brussels, Belgium) was placed in
each of the commissures for plication. The commisures
can more precisely be described as the three triangular
extensions of the left ventricular outflow tract which reach
to the level of the sinotubular junction [9]. A cryopre-
served pulmonary homograft was used for reconstruction
of the right ventricular outflow tract in the first 19 patients
and thereafter Contegra® valved conduit was used due to
nonavailability of the appropriate sized homograft.
Reconstruction of right ventricular outflow tract was done
before removing the aortic cross-clamp. The conduit for
reconstruction of right ventricular outflow tract was over-
sized whenever possible. The perfusion data is shown in
Table 2.
Follow-up
Early mortality was defined as any death within 30 days or
during initial hospitalization. Postoperative valve-related
morbidity and mortality were evaluated and reported
according to standard definitions [10]. All patients had a
clinical examination, New York Heart Association
functional class assessment, chest x-ray, electrocardio-
gram, and echocardiographic assessment before dis-
Table 1: Patient Characteristics
No. of patients 38
Male:female ratio 28:10
Age (years)
Mean (±SD) 13.1 ± 5.7
Median (range) 12.8 (1.4–29.7 years)
Body weight (kg) 41.3 ± 19.5
Height (cm) 142.9 ± 24.2
Body surface area (m2) 1.25 ± 0.40
Valve pathology
Bicuspid 20 (52.6)
Prosthesis 1 (2.6)
Endocarditis 1 (2.6)
Dysplastic tricuspid 16 (42.2)
Dominant hemodynamic lesion
Aortic stenosis 27 (71.1)
Aortic regurgitation 6 (15.7)
Mixed disease 5 (13.8)
Preoperative NYHA Class
Class I 23 (60.5)
Class II 12 (31.5)
Class III 3 (7.9)
Class IV -
Previous interventions for aortic valve 30 (78.9)
Balloon valvotomy 16* (42.1)
Surgical valvotomy 8 (21.1)
Balloon & surgical valvotomy 3 (7.9)
Valve repair 2 (5.3)
Valve replacement 1 (2.6)
Prior other surgical procedures
Coarctation repair 1 (2.6)
Ventricular septal defect closure 1 (2.6)
SD, standard deviation; cm, centimetre; kg, kilograms; m2, square metres. * 1 patient had balloon valvotomy × 2 while one had balloon valvotomy × 
3. Values in parentheses are percentages.BMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/3
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charge, at 3 to 6 months, and at yearly interval thereafter.
The echocardiographic assessment included color flow
Doppler to assess the severity of autograft insufficiency,
which was graded according to the method described by
Perry at al [11]. The peak transvalvular flow velocities
were measured with continuous wave Doppler and peak
gradients were calculated. The haemodynamics across the
pulmonary homograft and Contegra® conduit were also
measured.
Statistical analysis
Data are presented as mean ± SD (unless otherwise
stated). Patient survival analysis and time-to-event analy-
sis was performed using Kaplan-Meier methods. The
paired Student's t-test was used for analysis of the differ-
ences between measurements taken after surgery and at
the latest follow-up. A p < 0.05 was considered significant.
Statistical analysis was performed using Microsoft Excel
2000 and Statistical Package for the Social Sciences, ver-
sion 10.0 for Windows 2000 (SPSS, Chicago, Ill., USA).
Results
Survival
One patient died suddenly 11 days after surgery. Ventricu-
lar arrhythmia was suspected as the most likely cause. One
late death 3 years after surgery was also attributed to ven-
tricular arrhythmia. The child was brought to the accident
and emergency department in a state of shock. Initial
resuscitation was unsuccessful. Emergency sternotomy
did not reveal any obvious cause for the clinical presenta-
tion and patient died despite vigorous attempts to resusci-
tate.  Post mortem failed to reveal any pathology of the
valves or coronaries. Ventricular arrhythmia was sus-
pected as the most likely cause of death. The actuarial sur-
vival at 7 years was 94 ± 2.5% (Figure 3).
Morbidity
Conduction abnormalities and arrhythmias were the
commonest perioperative morbidity. 1 patient had
transient atrial fibrillation and 1 had nodal rhythm which
reverted back to sinus after 24 hours. Two patients had
nonsustained ventricular tachycardia limited to the first
24 hours. Two patients had ventricular ectopics which
Table 2: Operative and postoperative data
CPB time (minutes)
Mean 204 ± 48
Median (range) 194 (135–410)
Cross-clamp time (minutes)
Mean 133 ± 19
Median (range) 130 (101–185)
RVOT conduit
Homograft 25 (69.6)
Contegra© Bioprosthesis 13 (30.7)
Conduit size
Median (range) 23 (18–27 mm)
Ventilation time (hours) 11.4 ± 6.6
Use of inotropes 3 (7.9)
Arrhythmias
Transient atrial fibrillation 1 (2.6)
Nodal rhythm 1 (2.6)
Ventricular ectopics 2 (5.3)
Reverted malignant dysrrhythmia 2 (5.3)
Reexploration for bleeding 1 (2.6)
Pericardial effusion 2 (5.3)
Pleural effusion 2 (5.3)
Pneumothorax 3 (7.9)
ICU stay (days)
Mean (±SD) 1.8 ± 2.2
Median (range) 1 (1–13)
Hospital stay (days)
Mean (±SD) 9.8 ± 6.2
Median (range) 8 (6–42)
Mortality 2 (5.3)
Hospital death 1(2.6)
Late death 1(2.6)
Values in parentheses are percentages ICU, intensive care unit; RVOT, right ventricular outflow tract.BMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/3
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responded to correction of serum potassium levels. 3
patients required inotropic support in the first 12 hours
after surgery. However, inotropic support was gradually
weaned off over the next 24–48 hours. 1 patient had
reoperation for bleeding. 3 had pneumothorax secondary
to removal of chest drain. This was managed conserva-
tively. Two patients had pericardial effusion. 1 required
aspiration under echocardiographic guidance while the
other responded to conservative management with diuret-
ics. Two patients developed postoperative pleural effusion
which was managed conservatively. The duration of
mechanical ventilation, cardiac intensive care unit length
of stay, and total hospital length of stay are shown in
Table 2.
Functional status
Severity of dyspnoea was assessed by the New York Heart
Association classification. Preoperatively, 23 patients
(60.5%) were in New York Heart Association class I, 12
(31.5%) were in New York Heart Association class II and
3 (7.9%) were in class III. All except 3 patients were in
New York Heart Association class I at their last follow-up.
Autograft-related complications
In our series we did not experience any early or late
autograft complication necessitating autograft replace-
ment. Early or late clinically significant autograft leakage
was not seen. Other possible autograft-related complica-
tions such as bacterial valve endocarditis or thromboem-
bolic phenomena were also not encountered. None of the
patients required replacement of the autograft during the
follow-up period.
Echocardiographic follow-up of pulmonary autograft
Echocardiography demonstrated excellent autograft func-
tion. The peak aortic gradient which was 8.0 ± 3.0 milli-
metres of mercury at the time of discharge did not change
much as it was 7.8 ± 3.8 millimetres of mercury (p = 0.7)
at the latest follow-up. 11 patients showed trivial while 3
had mild aortic regurgitation at the time of discharge and
the degree of regurgitation remained static on color flow
Doppler at the latest follow-up.
Echocardiographic follow-up of right ventricular outflow 
tract reconstruction
Pulmonary homograft showed a significant increase in
peak gradient from 11.1 ± 3.8 millimetres of mercury after
surgery to 14.5 ± 7.1 millimetres of mercury (range, 5.8–
49 millimetres of mercury; p = 0.01). Two patients needed
balloon dilatation for pulmonary stenosis. Another 2
patients had a pulmonary homograft gradient of ≥40 mil-
limetres of mercury. 5 patients had mild while one patient
had moderate pulmonary homograft valve insufficiency.
They all are asymptomatic with normal right ventricular
function and minimal dilatation of right ventricle. None
of the patients needed reoperation due to homograft
dysfunction.
Contegra® conduit has been used since November 2000
for the reconstruction of right ventricular outflow tract in
all patients undergoing Ross procedure at our institution.
The use of Contegra® was prompted by the nonavailability
of appropriate sized homograft. Early echocardiographic
follow-up of this conduit has shown it to be a useful
replacement for pulmonary homograft. 3 patients were
diagnosed with mild regurgitation after surgery which has
remained stable at the latest follow-up. The peak gradient
of 11 ± 3.9 millimetres of mercury after surgery was 12.4
± 6.7 millimetres of mercury at the latest follow-up (p =
0.35).
Discussion
In our series excellent midterm results with physiologic
gradients and clinically insignificant incompetence, or
none at all, of the autograft have been achieved in the
majority of patients. There was one early and one late
death with an overall mortality rate in this series of 5.3%.
This is equivalent to that in prior reports [12-16]. The total
morbidity was also acceptably low while the rate of free-
dom from reoperation in our series is 100%.
We have performed all operations as root replacement.
This in our experience maintains the anatomy and the
three-dimensional geometry of the autograft and thus
results in a more consistently competent autograft valve
compared with the intraaortic techniques of subcoronary
implantation or inclusion root [17]. Moreover, using this
technique it is possible to completely remove all aortic
root components that are abnormal. A 100% freedom
from reoperation has been accomplished mainly if not
entirely by meticulous attention to technical detail. Trans-
ferring the pulmonary trunk as a complete free-standing
Kaplan-Meier survival Figure 3
Kaplan-Meier survival
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
01 22 43 64 86 07 2
Follow-up (months)
S
u
r
v
i
v
a
lBMC Cardiovascular Disorders 2004, 4 http://www.biomedcentral.com/1471-2261/4/3
Page 6 of 7
(page number not for citation purposes)
root into the aortic position seems to offer the best chance
for achieving an undistorted pulmonary valve. Size dis-
crepancy between the aortic root and the pulmonary
trunk is always corrected by adjustment of the size of the
aortic root.
No doubt that it is a technically demanding and time con-
suming procedure with cross clamping time more than
twice as long as for a simple aortic valve replacement with
mechanical or bioprostheses [18]. However, despite the
extra time of cardiac ischemia and long cardiopulmonary
bypass duration, the patients recover rapidly as evidenced
by short ICU stay time and duration of hospital stay. Per-
haps this is related to the optimal haemodynamic per-
formance associated with the Ross procedure.
Exercise performance after the operation is especially
impressive as shown by the New York Heart Association
class of study population at the latest follow-up, making
this operation helpful to athletic individuals and growing
children. We think that an important factor in determin-
ing optimal functional outcome after surgery is the actual
timing of intervention itself. Previously due to replace-
ment with prosthetic valves surgery was delayed in grow-
ing children to avoid repeated replacements. This would
result in deterioration of cardiac function especially in
children with aortic regurgitation. Since there are fewer
concerns regarding the need for early replacement of the
aortic valve after the Ross procedure [19], we tend to
replace the diseased aortic valve at an early stage especially
in children with aortic regurgitation. This is in agreement
with Cheung et al [20] who have concluded from their
study of children with aortic regurgitation having Ross
procedure that postponing intervention to a later stage of
the disease is more likely to be associated with a more
dilated ventricle, and disruption of the short axis architec-
ture, despite "successful surgical repair".
Another important finding of our study is the relatively
stable autograft valve function in patients with bicuspid
aortic valve. 20 patients in our study had bicuspid aortic
valve. Follow-up for 7 years has not shown any unusual
dilatation or valve dysfunction and therefore we can at
this point, based on our results, assume that Ross proce-
dure in patients with bicuspid aortic valve does not pre-
dispose to early autograft failure. However, a longer
follow-up is needed to substantiate this claim.
The pulmonary homograft in the right ventricular outflow
tract is regarded as the limiting factor in the long term suc-
cess of the Ross procedure. During follow-up, no reopera-
tion was needed for pulmonary homograft dysfunction
although two patients needed balloon dilatation for pul-
monary stenosis. In the present series, 8% (2/25) of the
patients had a gradient > 40 mm Hg across the homograft.
This was relatively high compared with some of the other
series [21,22]. Yet it substantiates the claim that the right
ventricular outflow tract is the predominant 'weak point'
of the Ross procedure [21]. Our explanation for lack of
reoperation for pulmonary homograft dysfunction even
after 7 years is that unlike aortic homograft, pulmonary
homograft lasts longer due to less intrinsic calcium and
thickness. Moreover, transcatheter techniques are now
well established and patients can have longer freedom
from reoperation as these techniques might be able to
extend the life of the homograft without reoperation.
Also, the threshold for surgical intervention in case of pul-
monary homograft insufficiency is high as it is often seen
that wide-open pulmonary insufficiency is tolerated for
15 to 20 years before right ventricular dilatation sets in.
Another important feature of our series is the use of Con-
tegra® for the reconstruction of right ventricular outflow
tract. Contegra® is a biological valved conduit consisting
of a glutaraldehyde-preserved heterologous bovine inter-
nal jugular vein having a trileaflet venous valve. Since
November 2000 Contegra® has been used in 13 patients at
our institution. Nonavailability of appropriate sized hom-
ograft prompted us to use the Contegra®. We have sepa-
rately published our results of the use of Contegra® in Ross
operation [23]. We find it to be an attractive option for use
as a homograft alternative in Ross operation. Our choice
is guided by the fact that this new conduit has provided
consistently good results in the first three years of its use
[24-28]. Only 3 patients developed mild regurgitation
after surgery which is stable upon follow-up and the
gradient across the valve has not shown a significant
increase. In addition, excellent off-the-shelf availability,
easy tailoring and suturing, large variety of available sizes
(12 to 22 millimetres internal diameter), no need for
proximal or distal extension and adequate hemodynamics
are some of the other advantages which make Contegra®
our first choice for right ventricular outflow tract recon-
struction after Ross operation [28].
Limitations of the study
It must be taken into consideration that this is a retrospec-
tive observational study with a relatively short median fol-
low-up period.
Conclusions
The pulmonary autograft, being the patient's own tissue,
is not subject to immunologic degenerative changes, is
free from risks associated with anticoagulation and offers
excellent haemodynamics. All these features make it an
excellent choice for children and young adults requiring
aortic valve replacement.
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